|
|
|
| Efficacy and Safety of Febuxostat Combination with Alprostadil in Treatment of Chronic Renal Failure and Influence Onhyperuricemia Andhemorheology |
| LI Zhicheng, TANG Zhigang, ZHENG Qiao, et al |
| Zigong First People's Hospital, Sichuan Zigong 643000, China |
|
|
|
|
Abstract Objective: To study the efficacy and safety of febuxostat combination withalprostadil in treatment of chronic renal failure and influence on hyperuricemia(UA) and hemorheology. Methods: 90 patients of chronic renal failure who received therapy from February 2015 to February 2018 in our hospital were selected as research objects,theywere divided into observation group (50 cases) and control group (40 cases) by simple random number table method,on the basis of routine treatment, the control group was treated with febuxostat, and the observation group was treated with Alprostadil for 8 weeks.The clinical efficacy, laboratory indexes, hemorheological changes and adverse reactions of the two groups were compared.Results: After treatment, the total effective rate of the observation group was significantly higher than those in the control group(P<0.05); there were significant differences in urea nitrogen (BUN), serum creatinine (Scr), 24-hour urinary protein, UA, whole blood high shear viscosity, whole blood low shear viscosity and plasma viscosity between groups at interblock·different time points(P<0.05);in the observation group, there were 2 cases of redness in the injection site during the intravenous injection of alprostadil, and there were no nausea and vomiting, obvious abnormal liver function, joint pain and other adverse reactions during the treatment of the two groups. Conclusion: Febuxostat combination withalprostadil is well for chronic renal failure, which can effectively improve blood hypercoagulability and renal function, reducing UA expression, and without increasing adverse drug reactions and has high clinical value.
|
|
|
|
|
|
[1] 雷三霞,于长国,曾春艳.高尿酸血症与肾损害相关性研究进展[J].医学综述,2014,20(10):1775~1777.
[2] Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation[J]. Am Kidney Dis, 2018, 71(6): 851~865.
[3] Ossorio-Garcia L, Jimenez-Gallo D, Arjona-Aguilera C, et al. Multimodal treatment of calciphylaxis with sodium thiosulfate, alprostadil, and hyperbaric oxygen therapy[J]. Actas Dermosifiliogr, 2016, 107(8): 695~697.
[4] 周如君,武英.前列地尔的剂型及临床研究进展[J].中国煤炭工业医学杂志,2014,17(11):1883~1887.
[5] 朱宣辑,牛丰,刘杨,等.2011例慢性肾衰竭住院患者的病因分析[J].中国实验诊断学,2014,18(11):1770~1772.
[6] Su X, Xie X, Liu L, et al. Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: a systematic review and bayesian network meta-analysis[J]. Am Kidney Dis, 2017, 69(1): 69~77.
[7] 孙婷婷,杨世诚,丛洪良,等.前列地尔对高血压患者行冠状动脉介入治疗后对比剂诱导的急性肾损伤的预防作用[J].中华高血压杂志,2016,24(8):741~745.
[8] 刘斌,李聃丹,钱净,等.促红细胞生成素联合前列地尔治疗急性肾损伤疗效观察[J].昆明医科大学学报,2014,35(10):91~95.
[9] 张瑾,张燕,杨宏.前列地尔对慢性肾功能衰竭患者血清炎症因子水平及营养生化指标的影响[J].中国生化药物杂志,2015,35(4):81~83,87. |
|
|
|
2019, Vol. 25 
